Patents by Inventor Ethan G. CERAMI

Ethan G. CERAMI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PIK3C2G fusions
    Patent number: 10875930
    Abstract: The invention provides to PIK3C2G (phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 gamma) gene fusions and PIK3C2G fusion proteins. The invention further provides methods of diagnosing and treating diseases or disorders associated with PK3C2G fusions, such as conditions mediated by aberrant PIK3C2G expression or activity, or conditions associated with overexpression of PIK.3C2G.
    Type: Grant
    Filed: July 30, 2014
    Date of Patent: December 29, 2020
    Assignee: BLUEPRINT MEDICINES CORPORATION
    Inventors: Nicolas Stransky, Ethan G. Cerami, Joseph L. Kim, Christoph Lengauer
  • PIK3CA fusions
    Patent number: 10669590
    Abstract: The invention provides PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha) gene fusions, and fragments of those gene fusions. The invention further provides methods of diagnosing and treating diseases or disorders associated with PIK3CA fusions, such as conditions mediated by PIK3CA aberrant expression or activity, or overexpression of PIK3CA.
    Type: Grant
    Filed: February 27, 2019
    Date of Patent: June 2, 2020
    Assignee: Blueprint Medicines Corporation
    Inventors: Ethan G. Cerami, Christoph Lengauer, Nicolas Stransky
  • NTRK2 FUSIONS
    Publication number: 20190389969
    Abstract: The invention provides to NTRK (“Neurotrophic Tyrosine Receptor Kinase) gene fusions, NTRK. fosion proteins, and fragments of those genes and polypeptides.
    Type: Application
    Filed: August 1, 2019
    Publication date: December 26, 2019
    Applicant: Blueprint Medicines Corporation
    Inventors: Nicolas STRANSKY, Ethan G. CERAMI, Christoph LENGAUER
  • NTRK2 fusions
    Patent number: 10407509
    Abstract: The invention provides to NTRK (“Neurotrophic Tyrosine Receptor Kinase) gene fusions, NTRK, fusion proteins, and fragments of those genes and polypeptides. The invention further provides methods of diagnosing and treating diseases or disorders associated with NTRK fusions, such as conditions mediated by aberrant NTRK expression or activity, or overexpression of NTRK.
    Type: Grant
    Filed: July 30, 2014
    Date of Patent: September 10, 2019
    Assignee: Blueprint Medicines Corporation
    Inventors: Nicolas Stransky, Ethan G. Cerami, Christoph Lengauer
  • FGR fusions
    Patent number: 10370725
    Abstract: FGR (feline Gardner-Rasheed sarcoma viral oncogene homolog) fusions are described herein. Further provided are methods of diagnosing and treating diseases or disorders associated with FGR fusions, such as conditions mediated by FGR aberrant activity, or overexpression.
    Type: Grant
    Filed: July 15, 2015
    Date of Patent: August 6, 2019
    Assignee: Blueprint Medicines Corporation
    Inventors: Nicolas Stransky, Ethan G. Cerami
  • PIK3CA FUSIONS
    Publication number: 20190185942
    Abstract: The invention provides PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha) gene fusions, and fragments of those gene fusions. The invention further provides methods of diagnosing and treating diseases or disorders associated with PIK3CA fusions, such as conditions mediated by PIK3CA aberrant expression or activity, or overexpression of PIK3CA.
    Type: Application
    Filed: February 27, 2019
    Publication date: June 20, 2019
    Applicant: BLUEPRINT MEDICINES CORPORATION
    Inventors: Ethan G. Cerami, Christoph Lengauer, Nicolas Stransky
  • FGR FUSIONS
    Publication number: 20170211149
    Abstract: FGR (feline Gardner-Rasheed sarcoma viral oncogene homolog) fusions are described herein. Further provided are methods of diagnosing and treating diseases or disorders associated with FGR fusions, such as conditions mediated by FGR aberrant activity, or overexpression.
    Type: Application
    Filed: July 15, 2015
    Publication date: July 27, 2017
    Applicant: BLUEPRINT MEDICINES CORPORATION
    Inventors: Nicolas Stransky, Ethan G. Cerami
  • PIK3CA FUSIONS
    Publication number: 20170044622
    Abstract: The invention provides PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) gene fusions, and fragments of those gene fusions. The invention further provides methods of diagnosing and treating diseases or disorders associated with PIK3CA fusions, such as conditions mediated by PIK3CA aberrant expression or activity, or overexpression of PIK3CA.
    Type: Application
    Filed: April 17, 2015
    Publication date: February 16, 2017
    Applicant: BLUEPRINT MEDICINES CORPORATION
    Inventors: Ethan G. Cerami, Christoph Lengauer, Nicolas Stransky
  • NTRK2 FUSIONS
    Publication number: 20160272725
    Abstract: The invention provides to NTRK (“Neurotrophic Tyrosine Receptor Kinase) gene fusions, NTRK. fusion proteins, and fragments of those genes and polypeptides. The invention further provides methods of diagnosing and treating diseases or disorders associated with NTRK fusions, such as conditions mediated by aberrant NTRK expression or activity, or overexpression of NTRK.
    Type: Application
    Filed: July 30, 2014
    Publication date: September 22, 2016
    Inventors: Nicolas STRANSKY, Ethan G. CERAMI, Christoph LENGAUER
  • PIK3C2G FUSIONS
    Publication number: 20160251446
    Abstract: The invention provides to PIK3C2G (phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 gamma) gene fusions and PIK3C2G fusion proteins. The invention further provides methods of diagnosing and treating diseases or disorders associated with PK3C2G fusions, such as conditions mediated by aberrant PIK3C2G expression or activity, or conditions associated with overexpression of PIK.3C2G.
    Type: Application
    Filed: July 30, 2014
    Publication date: September 1, 2016
    Inventors: Nicolas STRANSKY, Ethan G. CERAMI, Joseph L. KIM, Christoph LENGAUER